Abstract Background The coexistence of immune-mediated diseases and non-pharmacological immunosuppression states are rare might determine the natural history disease therapeutic decisions physician. IBD guidelines recommend screening for human immunodeficiency virus (HIV) before starting immunosuppressive treatment, but data on impact HIV infection its management in era biological drugs scarce....

Abstract Background Ustekinumab (UST) is an approved biologic for the treatment of adults with Crohn’s disease (CD). Through 16 weeks (wks), UST demonstrated high rates efficacy, low immunogenicity, and safety in paediatric patients (pts) similar to that observed adults.1 Here, we evaluated CD pts through 268 wks. Methods UniStar was a phase 1, multicentre, double-blind study (2-18 years old; b...

RATIONALE The fundamental pathogenesis of Behçet disease (BD) is still unclear and controversial. Many cases of oral aphthous ulcers and genital ulcers related to BD are reported; nevertheless, idiopathic giant esophageal ulcers related to BD are rare. A rare case for esophageal ulcers related to BD is presented. PATIENT CONCERNS In China, BD is represented with esophageal involvement which i...

HLA-B27 is a Major Histocompatibility Complex (MHC) class I molecule whose predominant function is the presentation of short 8-10 amino acid long peptides to cytotoxic CD8+T cells. HLA-B27 exhibits a strong association with a group of inflammatory arthritic diseases referred to as the spondyloarthropathies (SpAs) [1]. The SpAs are characterized by inflammation at the entheses, followed by skele...

Background: Inflammatory bowel disease (IBD) therapy, including immunomodulatory (IMM), corticosteroids (CS), and TNF inhibitors (TNFI), is known to increase the infectious risk when used in to treat many diseases. No recent studies have analyzed the incidence of infections in elderly patients on these therapies. We aim to analyze the effect of immunosuppressant use and age on infectious compli...

I. Steenholdt C, Enevold C, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease. Aliment Pharmacol Ther. 2012;36:650-659. II. Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Fallingborg J, Christensen L...